EirGenix Inc. to expand the capacity for CDMO business and the internal product commercialization. Production Line Expansion for Mammalian cell culture and Production Equipment at Zhubei Facility.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
80.3 TWD | +1.52% | +0.88% | -20.10% |
05-15 | EirGenix Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
03-22 | EirGenix Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-20.10% | 748M | |
-2.29% | 89.38B | |
-3.95% | 37.92B | |
-13.07% | 32.04B | |
+63.05% | 26.03B | |
-22.14% | 14.14B | |
-7.96% | 12.88B | |
-9.33% | 11.77B | |
-46.33% | 10.85B | |
+5.77% | 8.92B |
- Stock Market
- Equities
- 6589 Stock
- News EirGenix Inc.
- EirGenix Inc. Announces Production Line Expansion and Production Equipment at Zhubei Facility